after stratification for the extent of disease , previously untreated patients with small cell lung cancer randomized to receive therapy with the four-drug combination of cyclophosphamide , oncovin , nimustine hydrochloride ( acnu ) , and procarbazine ( conp ) every four weeks ( continuous regimen ) or to receive conp alternating with the three-drug combination of etoposide ( vp-16 ) , adriamycin and cisplatin ( vad ) at four-week intervals ( alternating regimen ) .
C0771987
nimustine hydrochloride
C0028096
acnu